About The Study: In this binational study of older adults with diabetes, nearly 6 in 10 U.S. adults and 3 in 10 Japanese adults discontinued glucagon-like peptide-1 receptor agonists (GLP-1RAs) within 12 months of initiating injectable semaglutide. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates in both countries, which is troublesome given the substantial clinical benefit these high-risk individuals would be expected to derive from GLP-1RA therapy.
Corresponding Author: To contact the corresponding author, Dhruv S. Kazi, MD, MSc, MS, email dkazi@bidmc.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2025.3109)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3109?guestAccessKey=28d146b1-0d26-4c68-959a-d0f87f734531&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425
JAMA Cardiology